CA3047449C - Combination of a protein kinase inhibitor and an additional chemotherapeutic agent - Google Patents

Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Download PDF

Info

Publication number
CA3047449C
CA3047449C CA3047449A CA3047449A CA3047449C CA 3047449 C CA3047449 C CA 3047449C CA 3047449 A CA3047449 A CA 3047449A CA 3047449 A CA3047449 A CA 3047449A CA 3047449 C CA3047449 C CA 3047449C
Authority
CA
Canada
Prior art keywords
compound
nci
etoposide
lung
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3047449A
Other languages
English (en)
French (fr)
Other versions
CA3047449A1 (en
Inventor
Lars DAMSTRUP
Thomas GROMBACHER
Christian Sirrenberg
Lyubomir VASSILEV
Astrid Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3047449A1 publication Critical patent/CA3047449A1/en
Application granted granted Critical
Publication of CA3047449C publication Critical patent/CA3047449C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3047449A 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent Active CA3047449C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436046P 2016-12-19 2016-12-19
US62/436,046 2016-12-19
PCT/EP2017/083272 WO2018114776A1 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Publications (2)

Publication Number Publication Date
CA3047449A1 CA3047449A1 (en) 2018-06-28
CA3047449C true CA3047449C (en) 2023-07-04

Family

ID=60915499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047449A Active CA3047449C (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Country Status (8)

Country Link
US (1) US11246929B2 (enExample)
EP (1) EP3554495B1 (enExample)
JP (1) JP7113826B2 (enExample)
KR (1) KR102607967B1 (enExample)
AU (1) AU2017384134B2 (enExample)
CA (1) CA3047449C (enExample)
ES (1) ES3040063T3 (enExample)
WO (1) WO2018114776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2020259613A1 (zh) * 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为dna-pk抑制剂的喹啉和噌啉衍生物
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
CN1861050A (zh) 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
SG188802A1 (en) 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
RS61664B1 (sr) * 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk

Also Published As

Publication number Publication date
EP3554495B1 (en) 2025-06-04
CA3047449A1 (en) 2018-06-28
JP2020502182A (ja) 2020-01-23
AU2017384134B2 (en) 2022-03-24
AU2017384134A1 (en) 2019-08-01
JP7113826B2 (ja) 2022-08-05
KR102607967B1 (ko) 2023-11-29
WO2018114776A1 (en) 2018-06-28
US11246929B2 (en) 2022-02-15
ES3040063T3 (en) 2025-10-28
EP3554495A1 (en) 2019-10-23
US20190365896A1 (en) 2019-12-05
KR20190099253A (ko) 2019-08-26

Similar Documents

Publication Publication Date Title
US20200368235A1 (en) Ibrutinib combination therapy
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
US20250352598A1 (en) Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
EP3429614B1 (en) Method of treating triple negative breast cancer
CA3047449C (en) Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
JP2018513185A (ja) 共結晶組成物及びその医薬用途
KR20250121432A (ko) Mta-협력 prmt5 저해제를 사용한 암 치료
WO2020114348A1 (en) Methods for cancer therapy
JP7783217B2 (ja) アズブジンを含む抗腫瘍医薬組成物
CN105476996B (zh) 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN100475212C (zh) 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合
JP2017509671A (ja) カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
RU2785997C1 (ru) Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
Al-Muswie et al. Colon Cancer: Risk Factors and Therapeutic Approaches
US20200397738A1 (en) Methods for treating cancer and protecting renewable tissues
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
EP4591868A1 (en) Medicament for preventing and treating tumor and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921